Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment protocol for extracranial germ cell tumours
2004-002503-33Phase 4Completed
- Sponsor
- Our Lady's Children's Hospital, Crumlin
- Start
- May 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carboplatin, etoposide and bleomycin in extracranial germ cell tumor (EGCT), sponsored by Our Lady's Children's Hospital, Crumlin. Primary endpoints: 12-month event rate in low-risk patients, Interim stopping boundary after first 10 low-risk patients and 4 more. Started May 2006; status: completed.
02
Drugs
carboplatinetoposidebleomycin
03
Conditions
extracranial germ cell tumor (EGCT)
Beyond the preview
Go deeper on 2004-002503-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002503-33.